Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 526 - 550 of 15273 in total

Sparsentan

Sparsentan is a dual antagonist of the endothelin type A receptor (ETAR) and the angiotensin II (Ang II) type 1 receptor (AT1R) with a similar affinity for both (9.3 nM for ETAR and 0.8 nM for AT1R).[A257330,L45300] Sparsentan is first in its class and orally active, and was created by...
Approved
Investigational
Matched Description: … [A257330,L45300] Sparsentan is first in its class and orally active, and was created by merging the structural ... Sparsentan is a dual antagonist of the endothelin type A receptor (ETAR) and the angiotensin ... [L45315] The use of sparsentan may cause hepatotoxicity and embryo-fetal toxicity.[L45300] …
Matched Categories: … Sulfur Compounds …

Parthenolide

Parthenolide has been used in trials studying the diagnostic of Allergic Contact Dermatitis.
Approved
Investigational

Methoxyphenamine

Approved

Fluticasone

Fluticasone is a synthetic glucocorticoid available as 2 esters, DB08906 and DB00588[F4355,F4358,F4361,F4364][FDA Label]. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications[F4355,F4358,F4361,F4364][FDA Label]. DB00588 was first approved in 1990 and DB08906 was approved in 2007 .
Approved
Experimental
Matched Description: … [DB00588] was first approved in 1990[L5962] and [DB08906] was approved in 2007[L5965]. ... Fluticasone is a synthetic glucocorticoid available as 2 esters, [DB08906] and [DB00588][F4355,F4358, ... These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory …
Matched Categories: … formoterol and fluticasone ... salmeterol and fluticasone …

Ivosidenib

Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivosidenib was granted accelerated approval by the FDA...
Approved
Investigational
Matched Description: … and proliferation. ... IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth ... [A248750] Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Betaxolol

A cardioselective beta-1-adrenergic antagonist with no partial agonist activity.
Approved
Investigational
Matched Categories: … Antiglaucoma Preparations and Miotics …

Milrinone

Heart failure is a multifactorial condition that affects roughly 1-2% of the adult population. Often the result of long-term myocardial ischemia, cardiomyopathy, or other cardiac insults, heart failure results from an inability of the heart to perfuse peripheral tissues with sufficient oxygen and metabolites, resulting in complex systemic pathologies. Heart...
Approved
Matched Description: … and peripheral vasodilation in acute decongested heart failure. ... failure results from an inability of the heart to perfuse peripheral tissues with sufficient oxygen and ... cyclic adenosine monophosphate (cAMP) production, which affects the heart's contractile function and …

Butorphanol

A synthetic morphinan analgesic with narcotic antagonist action. It is used in the management of severe pain.
Approved
Illicit
Vet approved

Eplerenone

Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of...
Approved
Matched Description: … antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and ... The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the ... mineralocorticoid receptors relative to its binding to recombinant human glucocorticoid, progesterone and …
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists …

Nalbuphine

A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States.
Approved
Matched Description: … It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid …

Almotriptan

Almotriptan is a triptan drug for the treatment of migraine headaches. Almotriptan is in a class of medications called selective serotonin receptor agonists. It works by narrowing blood vessels in the brain, stopping pain signals from being sent to the brain, and stopping the release of certain natural substances that...
Approved
Investigational
Matched Description: … works by narrowing blood vessels in the brain, stopping pain signals from being sent to the brain, and ... stopping the release of certain natural substances that cause pain, nausea, and other symptoms of migraine …
Matched Categories: … Serotonin-1b and Serotonin-1d Receptor Agonist …

Finasteride

Finasteride is a synthetic 4-azasteroid compound and specific inhibitor of steroid Type II 5α-reductase, which is an intracellular enzyme that converts the androgen testosterone into 5α-dihydrotestosterone (DHT). It works in a similar fashion as dutasteride, which is another 5-alpha-reductase inhibitor, by exerting antiandrogenic effects. Finasteride is an orally active drug...
Approved
Matched Description: … Finasteride is a synthetic 4-azasteroid compound [L10565] and specific inhibitor of steroid Type II 5α-reductase ... [L6244] Finasteride is commonly marketed under the brand names Propecia and Proscar to be used aloneo ... first approved by the FDA in 1992 for the treatment of benign prostatic hyperplasia to improve symptoms and …
Matched Categories: … doxazosin and finasteride ... alfuzosin and finasteride ... finasteride and tadalafil ... Skin and Mucous Membrane Agents ... Genito Urinary System and Sex Hormones …

Dalfampridine

Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.
Approved

Patent Blue

Patent blue is aniline dye and it is one of the most common dyes used. It is a sodium or calcium salt of diethylammonium hydroxide inner salt. It has the chemical designation of (4-(alpha-(p-(diethylamino)phenyl)-2,4-disulfobenzylidene)-2,5-cyclohexadiene-1-ylidene)diethylammonium hydroxide. Patent blue was developed by Guerbet and approved by Health Canada on December 31, 1979....
Approved
Matched Description: … Patent blue is aniline dye and it is one of the most common dyes used. ... Patent blue was developed by Guerbet and approved by Health Canada on December 31, 1979. …

Tolbutamide

Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin...
Approved
Investigational
Matched Description: … Tolbutamide and its metabolites are excreted in urine (75-85%) and feces. ... It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea ... increase the number and sensitivity of insulin receptors. …
Matched Categories: … Sulfur Compounds ... Alimentary Tract and Metabolism ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …

Valdecoxib

Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.
Approved
Investigational
Withdrawn
Matched Description: … ., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke …
Matched Categories: … Sulfur Compounds ... Genito Urinary System and Sex Hormones ... Antiinflammatory and Antirheumatic Products ... Gynecological Antiinfectives and Antiseptics ... Antiinflammatory and Antirheumatic Products, Non-Steroids …

Dinutuximab

Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions...
Approved
Investigational
Matched Description: … 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who ... It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the ... constant regions of human IgG1 heavy-chain and kappa light-chain. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Imatinib

Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with...
Approved
Matched Description: … responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and ... [L42220] Imatinib was approved on February 1st ,2001 by the FDA and November 7th, 2001 by the EMA …
Matched Categories: … Benzamides and benzamide derivatives ... Antineoplastic and Immunomodulating Agents …

Trazodone

Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine receptor inhibitor (SNRIs) in the...
Approved
Investigational
Matched Description: … Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors ... [A181180] It is used in adults and has been shown to be comparable in efficacy to other drugs such as ... promote the anxiety symptoms, sexual symptoms, or insomnia, which are commonly associated with SSRI and …
Matched Categories: … Serotonin antagonist and reuptake inhibitors (SARIs) …

Sincalide

Sincalide is a medication given by injection to assist in the diagnosis of gallbladder and pancreas disorders. It is identified as the 8-amino acid C-terminal segment of cholecystokinin and is also known as CCK-8. Naturally occurring cholecystokinin is a gastrointestinal peptide hormone normally essential for stimulating protein and fat digestion...
Approved
Matched Description: … It is identified as the 8-amino acid C-terminal segment of cholecystokinin and is also known as _CCK- ... Furthermore, sincalide stimulates the pancreatic secretion of bicarbonate and enzymes. ... Sincalide is a medication given by injection to assist in the diagnosis of gallbladder and pancreas disorders …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Nilotinib

Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant...
Approved
Investigational
Matched Description: … A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Desonide

A nonfluorinated corticosteroid anti-inflammatory agent used topically for dermatoses.
Approved
Investigational
Matched Categories: … desonide and antiseptics …

Fursultiamine

Compound used for therapy of thiamine deficiency. It has also been suggested for several non-deficiency disorders but has not yet proven useful. Fursultiamine is a vitamin B1 derivative.
Approved
Matched Categories: … Sulfur Compounds …

Ethanolamine oleate

Ethanolamine oleate is a mild sclerosing agent. It is composed of ethanolamine, a basic substance, which when combined with oleic acid forms a clear, straw to pale yellow colored, deliquescent oleate.
Approved
Matched Iupac: … (9Z)-octadec-9-enoic acid; 2-aminoethan-1-ol …
Matched Description: … It is composed of ethanolamine, a basic substance, which when combined with oleic acid forms a clear, …

Betahistine

Ménière's disease is a progressive disease of the inner ear characterized by vertigo, tinnitus, and hearing loss. It has a significant impact on both the physical and social functioning of affected individuals.[A220318,L16408] Betahistine is a histamine-like antivertigo drug used for treating symptoms associated with Ménière's disease. It is thought to...
Approved
Investigational
Matched Description: … It has a significant impact on both the physical and social functioning of affected individuals. ... Ménière's disease is a progressive disease of the inner ear characterized by vertigo, tinnitus, and hearing …
Displaying drugs 526 - 550 of 15273 in total